This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (272)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA

A Randomized Controlled Trial

John J. Treanor, MD; Frederick G. Hayden, MD; Peter S. Vrooman, MD; Rick Barbarash, PharmD; Robert Bettis, MD; Dennis Riff, MD; Sudeep Singh, MD; Nelson Kinnersley; Penelope Ward, MD; Roger G. Mills, MD; for the US Oral Neuraminidase Study Group

JAMA. 2000;283:1016-1024.

Context  Previous studies have shown oseltamivir, a neuraminidase inhibitor, to be effective in preventing influenza and treating experimental influenza.

Objective  To evaluate the efficacy and safety of oseltamivir in the treatment of naturally acquired influenza infection.

Design  Randomized, placebo-controlled, double-blind study conducted January through March 1998.

Setting  Sixty primary care and university health centers throughout the United States.

Participants  A total of 629 healthy nonimmunized adults aged 18 to 65 years with febrile respiratory illness of no more than 36 hours' duration with temperature of 38°C or more plus at least 1 respiratory symptom and 1 constitutional symptom.

Interventions  Individuals were randomized to 1 of 3 treatment groups with identical appearing pills: oral oseltamivir phosphate, 75 mg twice daily (n = 211) or 150 mg (n = 209) twice daily, or placebo (n = 209).

Main Outcome Measures  Duration and severity of illness in individuals infected with influenza.

Results  Two individuals withdrew before receiving medication and were excluded from further analyses. A total of 374 individuals (59.6%) were infected with influenza. Their duration of illness was reduced by more than 30% with both oseltamivir, 75 mg twice daily (median, 71.5 hours; P<.001), and oseltamivir, 150 mg twice daily (median, 69.9 hours; P = .006), compared with placebo (median, 103.3 hours). Severity of illness was reduced by 38% (median score, 597 score-hours; P<.001) with oseltamivir, 75 mg twice daily, and by 35% (median score, 626 score-hours; P<.001) with oseltamivir, 150 mg twice daily, vs placebo (median score, 963 score-hours). Oseltamivir treatment reduced the duration of fever and oseltamivir recipients returned to usual activities 2 to 3 days earlier than placebo recipients (P.05). Secondary complications such as bronchitis and sinusitis occurred in 15% of placebo recipients compared with 7% of combined oseltamivir recipients (P = .03). Among all 629 subjects, oseltamivir reduced illness duration (76.3 hours and 74.3 hours for 75 mg and 150 mg, respectively, vs 97.0 hours for placebo; P = .004 for both comparisons) and illness severity (686 score-hours and 629 score-hours for 75 mg and 150 mg, respectively, vs 887 score-hours for placebo; P<.001 for both comparisons). Nausea and vomiting occurred more frequently in both oseltamivir groups (combined, 18.0% and 14.1%, respectively; P = .002) than in the placebo group (7.4% and 3.4%; P<.001).

Conclusions  Our data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications.

Author Affiliations: University of Rochester, Rochester, NY (Dr Treanor); University of Virginia, Charlottesville (Dr Hayden); PW Clinical Research, Winston-Salem, NC (Dr Vrooman); Hill Top Research, St Louis, Mo (Dr Barbarash); Edmonds Family Medicine Clinic, Edmonds, Wash (Dr Bettis); Advanced Clinical Research Institute, Anaheim, Calif (Dr Riff); SARC Research Center, Fresno, Calif (Dr Singh); Roche Global Development, Welwyn, England (Mr Kinnersley and Dr Ward); and Gilead Sciences, Foster City, Calif (Dr Mills).

RELATED ARTICLES

Expanding the Treatment Options for Influenza
Richard P. Wenzel
JAMA. 2000;283(8):1057-1059.
EXTRACT | FULL TEXT  

February 23, 2000
JAMA. 2000;283(8):1079-1080.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identification of the Progenitors of Indonesian and Vietnamese Avian Influenza A (H5N1) Viruses from Southern China
Wang et al.
J. Virol. 2008;82:3405-3414.
ABSTRACT | FULL TEXT  

Estimates of the reproduction numbers of Spanish influenza using morbidity data
Vynnycky et al.
Int J Epidemiol 2007;36:881-889.
ABSTRACT | FULL TEXT  

Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects
Schentag et al.
J Clin Pharmacol 2007;47:689-696.
ABSTRACT | FULL TEXT  

Comparison of the MChip to Viral Culture, Reverse Transcription-PCR, and the QuickVue Influenza A+B Test for Rapid Diagnosis of Influenza
Mehlmann et al.
J. Clin. Microbiol. 2007;45:1234-1237.
ABSTRACT | FULL TEXT  

Avian influenza: A review
Thomas and Noppenberger
Am J Health Syst Pharm 2007;64:149-165.
ABSTRACT | FULL TEXT  

Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada
Skowronski et al.
CMAJ 2007;176:47-53.
ABSTRACT | FULL TEXT  

Comparison of the Influenza Virus-Specific Effector and Memory B-Cell Responses to Immunization of Children and Adults with Live Attenuated or Inactivated Influenza Virus Vaccines
Sasaki et al.
J. Virol. 2007;81:215-228.
ABSTRACT | FULL TEXT  

Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic
Lim
Thorax 2007;62:1-46.
FULL TEXT  

Emergence and predominance of an H5N1 influenza variant in China
Smith et al.
Proc. Natl. Acad. Sci. USA 2006;103:16936-16941.
ABSTRACT | FULL TEXT  

Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects
Abe et al.
The Annals of Pharmacotherapy 2006;40:1724-1730.
ABSTRACT | FULL TEXT  

The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis
Robson et al.
Nephrol Dial Transplant 2006;21:2556-2562.
ABSTRACT | FULL TEXT  

Insights into the Interaction between Influenza Virus and Pneumococcus
McCullers
Clin. Microbiol. Rev. 2006;19:571-582.
ABSTRACT | FULL TEXT  

Cost-effectiveness of universal influenza vaccination in a pregnant population.
Roberts et al.
Obstet Gynecol 2006;107:1323-1329.
ABSTRACT | FULL TEXT  

Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial
Predy et al.
CMAJ 2005;173:1043-1048.
ABSTRACT | FULL TEXT  

Neuraminidase inhibitors for influenza.
Moscona
NEJM 2005;353:1363-1373.
FULL TEXT  

Avian influenza A (H5N1) infection in humans.
Beigel
NEJM 2005;353:1374-1385.
FULL TEXT  

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia
Am. J. Respir. Crit. Care Med. 2005;171:388-416.
FULL TEXT  

The Novel Parainfluenza Virus Hemagglutinin-Neuraminidase Inhibitor BCX 2798 Prevents Lethal Synergism between a Paramyxovirus and Streptococcus pneumoniae
Alymova et al.
Antimicrob. Agents Chemother. 2005;49:398-405.
ABSTRACT | FULL TEXT  

Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation
Kotloff et al.
Am. J. Respir. Crit. Care Med. 2004;170:22-48.
ABSTRACT | FULL TEXT  

A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
Oxford et al.
J Antimicrob Chemother 2004;53:133-136.
ABSTRACT | FULL TEXT  

Multiplex Real-Time PCR Assay for Detection of Influenza and Human Respiratory Syncytial Viruses
Boivin et al.
J. Clin. Microbiol. 2004;42:45-51.
ABSTRACT | FULL TEXT  

Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors
McSharry et al.
CVI 2004;11:21-28.
ABSTRACT | FULL TEXT  

A Cost-Benefit Analysis of Testing for Influenza A in High-Risk Adults
Hueston and Benich
Ann Fam Med 2004;2:33-40.
ABSTRACT | FULL TEXT  

Management of Influenza in Adults Older than 65 Years of Age: Cost-Effectiveness of Rapid Testing and Antiviral Therapy
Rothberg et al.
ANN INTERN MED 2003;139:321-329.
ABSTRACT | FULL TEXT  

Comparison of the Directigen Flu A+B Test, the QuickVue Influenza Test, and Clinical Case Definition to Viral Culture and Reverse Transcription-PCR for Rapid Diagnosis of Influenza Virus Infection
Ruest et al.
J. Clin. Microbiol. 2003;41:3487-3493.
ABSTRACT | FULL TEXT  

Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations
Kaiser et al.
Arch Intern Med 2003;163:1667-1672.
ABSTRACT | FULL TEXT  

A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals
Ferguson et al.
J Antimicrob Chemother 2003;51:977-990.
ABSTRACT | FULL TEXT  

The Prevalence of Myocarditis and Skeletal Muscle Injury During Acute Viral Infection in Adults: Measurement of Cardiac Troponins I and T in 152 Patients With Acute Influenza Infection
Greaves et al.
Arch Intern Med 2003;163:165-168.
ABSTRACT | FULL TEXT  

The treatment of influenza with antiviral drugs
Stiver
CMAJ 2003;168:49-57.
ABSTRACT | FULL TEXT  

Early administration of oral oseltamivir increases the benefits of influenza treatment
Aoki et al.
J Antimicrob Chemother 2003;51:123-129.
ABSTRACT | FULL TEXT  

{blacktriangledown}Oseltamivir for influenza
DTB 2002;40:89-91.
ABSTRACT | FULL TEXT  

Nasal Swab versus Nasopharyngeal Aspirate for Isolation of Respiratory Viruses
Heikkinen et al.
J. Clin. Microbiol. 2002;40:4337-4339.
ABSTRACT | FULL TEXT  

A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site
Gubareva et al.
J. Gen. Virol. 2002;83:2683-2692.
ABSTRACT | FULL TEXT  

Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson et al.
BMJ 2002;325:652-654.
FULL TEXT  

Influenza Burden of Illness: Estimates From a National Prospective Survey of Household Contacts in France
Carrat et al.
Arch Intern Med 2002;162:1842-1848.
ABSTRACT | FULL TEXT  

In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta et al.
Antimicrob. Agents Chemother. 2002;46:977-981.
ABSTRACT | FULL TEXT  

Oral Administration of Cyclopentane Neuraminidase Inhibitors Protects Ferrets against Influenza Virus Infection
Sweet et al.
Antimicrob. Agents Chemother. 2002;46:996-1004.
ABSTRACT | FULL TEXT  

In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication
Kati et al.
Antimicrob. Agents Chemother. 2002;46:1014-1021.
ABSTRACT | FULL TEXT  

Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants
Gubareva et al.
Antimicrob. Agents Chemother. 2001;45:3403-3408.
ABSTRACT | FULL TEXT  

Diagnosis of Influenza in the Community: Relationship of Clinical Diagnosis to Confirmed Virological, Serologic, or Molecular Detection of Influenza
Zambon et al.
Arch Intern Med 2001;161:2116-2122.
ABSTRACT | FULL TEXT  

Influenza: vaccination and treatment
Stephenson and Nicholson
Eur Respir J 2001;17:1282-1293.
ABSTRACT | FULL TEXT  

Influenza : Will New Diagnostic Tests and Antiviral Drugs Make a Difference?
Coonrod
Chest 2001;119:1630-1632.
FULL TEXT  

Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Niederman et al.
Am. J. Respir. Crit. Care Med. 2001;163:1730-1754.
FULL TEXT  

Clinical Signs and Symptoms Predicting Influenza Infection
Hak et al.
Arch Intern Med 2001;161:1351-1352.
FULL TEXT  

In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201
Sidwell et al.
Antimicrob. Agents Chemother. 2001;45:749-757.
ABSTRACT | FULL TEXT  

Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts: A Randomized Controlled Trial
Welliver et al.
JAMA 2001;285:748-754.
ABSTRACT | FULL TEXT  

Influenza: Prospects for Control
Couch
ANN INTERN MED 2000;133:992-998.
ABSTRACT | FULL TEXT  

Prevention and Treatment of Influenza
Couch
NEJM 2000;343:1778-1787.
FULL TEXT  

Influenza
Cifu and Levinson
JAMA 2000;284:2847-2849.
FULL TEXT  

Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults
Kaiser et al.
Arch Intern Med 2000;160:3234-3240.
ABSTRACT | FULL TEXT  

Preventing Influenza in Healthy Adults: The Evolving Story
Monto
JAMA 2000;284:1699-1701.
FULL TEXT  

Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
KASISKE et al.
J. Am. Soc. Nephrol. 2000;11:S1-S86.
ABSTRACT | FULL TEXT  

Zanamivir speeds symptom relief in influenza
Nichol
Evid. Based Med. 2000;5:80-80.
FULL TEXT  

Oseltamivir once or twice daily safely prevented influenza
Nichol
Evid. Based Med. 2000;5:81-81.
FULL TEXT  

In Support of the Flu Pill
Journal Watch Dermatology 2000;2000:17-17.
FULL TEXT  

In Support of the Flu Pill
JWatch General 2000;2000:5-5.
FULL TEXT  

Expanding the Treatment Options for Influenza
Wenzel
JAMA 2000;283:1057-1059.
FULL TEXT